<gum class="diztwq"></gum>

og视讯app(中国)

Be the most trusted biotech company

2022-06-20

Henlius Attends BIO 2022
2022-06-17

First Subject Dosed in Phase 3 MRCT of Denosumab Biosimilar HLX14
2022-06-13

Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries
2022-06-07

First Subject Dosed of the Phase 1 Clinical Trial on Henlius Novel Anti-EGFR×4-1BB Bispecific Antibody HLX35 for the Treatment of Advanced or Metastatic Solid Tumours
2022-05-24

Henlius and Abbott Entered into a Semi-Exclusive License Agreement of HANLIKANG and HANQUYOU in Brazil
2022-05-19

First Patient Dosed for MRCT Phase 3 Studies on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab
2022-05-18

Phase 3 Clinical Study of Henlius Anti-PD-1 mAb, Serplulimab, in Combination with Chemotherapy for Treatment on Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints
2022-05-11

Henlius and Eurofarma Entered into a License Agreement for Henlius' 3 Products in Latin America
2022-04-29

IND Application of Phase I Clinical Trial of HANSIZHUANG in combination with Innovative Anti-LAG-3 mAb for the Treatment of Advanced/Metastatic Solid Tumours or Lymphomas Patients was Approved by NMPA